ImmunityBio Broadens European Reach of ANKTIVA with Strategic Expansion Move
Published: 20 Feb 2026
Author: Precedence Research
ImmunityBio, Inc. has announced a major expansion of access to its cancer immunotherapy ANKTIVA (nogapendekin alfa inbakicept) across Europe, marking a significant milestone in the company’s global growth strategy. The company has partnered with Accord Healthcare for distribution and commercialization support to increase its commercial presence in the area. To oversee operations and enable a planned European rollout, ImmunityBio has also formed a new subsidiary in Ireland. Accelerated patient access to cutting-edge immunotherapy treatments in several EU markets is the goal of this action.
The European Commission approved the expansion after granting conditional marketing authorization for ANKTIVA and Bacillus Calmette-Guerin (BCG). Adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, either with or without papillary tumors, are the target audience for this treatment. Given that there have historically been few treatment options available in Europe for this patient group, this approval marks a significant advancement. The authorization permits the therapy to be sold in all member states of the European Union as well as in a few other European nations.
ImmunityBio intends to use an established commercial infrastructure in conjunction with Accord Healthcare to guarantee efficient distribution and physician outreach. To raise awareness among medical professionals, Accord’s skilled field teams will assist with marketing medical engagement and educational initiatives. To provide eligible patients with wider and more effective access to the treatment, the partnership will combine ImmunityBio’s clinical innovation with Accord’s regional knowledge.
ImmunityBio's larger goal of revolutionizing cancer treatment through immune-based therapies is in line with the company's European expansion, according to company leadership. It is anticipated that the establishment of its Irish subsidiary will simplify long-term market development initiatives throughout Europe, regulatory coordination, and logistics. This most recent action reaffirms ImmunityBio’s dedication to providing innovative immunotherapies to patients with substantial unmet medical needs as it pursues more clinical research and geographic expansions.
In terms of its long-term commercialization roadmap, the company views Europe as a crucial growth market. In addition to expanding access to treatments soon, ImmunityBio hopes to create a solid basis for upcoming oncology product launches by fortifying regional infrastructure and establishing strategic partnerships. The increased availability of ANKTIVA is a result of the company's strategy to improve global patient reach and spur ongoing innovation in cancer immunotherapy by combining regulatory advancements, operational growth, and cooperative partnerships.